App. No. 19/562,541

Strategy check: re-ranked from #5 — Claim 1 recites the carrier properties in the alternative ('at least one of'), so the rank-1 pore-diameter misread cannot carry claim 1 (surface-area and pore-volume prongs still stand), whereas the motivation attack targets the essential combination that supplies any carrier property.

motivation to further define Friedman's porous silica with Nowak's silica properties

The stated motivation is that defining Friedman's porous silica with Nowak's silica properties 'would have yielded no more than the predictable results, e.g., enhanced properties of the composition obtained by using silica.' Counsel may argue this is a generalized, conclusory assertion that does not supply the articulated factual underpinning KSR and § 2143.01 require, particularly given that Friedman is a specific four-component self-emulsifying system (cannabinoid, terpene/essential oil, at least two emulsifiers, adsorbing powder) and Nowak is a two-active multiparticulate platform. The examiner has not explained why a PHOSITA would select Nowak's particular carrier parameters, as opposed to any of countless silica grades, to improve Friedman specifically.

• —Office action: 'It would have been obvious to further define porous silica of Friedman with properties of Nowak's silica and such properties of silica would have yielded no more than the predictable results, e.g., enhanced properties of the composition obtained by using silica.'

Risk The bar under KSR is low; the examiner may supplement on reconsideration with rationale (A) (combining known elements for predictable results) or (C)/(D) (known technique to improve a similar product), and both references address the same solubility/bioavailability problem, which supports a design-incentive rationale.

Strategy check: re-ranked from #7 — The current top for claim 15 is rank 5; the CBD-amount argument (rank 7) is directed to the specific added loading limitation, though the endpoint overlap means the examiner may invoke MPEP §2144.05 and evidence may be needed.

cannabidiol is present at an amount ranging from about 15% to about 40% by weight

The examiner relies on the overlap of Friedman's 0.01-20% cannabinoid range with the claimed 15-40%, but that overlap is a narrow sliver (roughly 15-20%). Friedman's grounded claim 2 recites a preferred cannabinoid concentration of 'about 0.2% w/w to about 5% w/w' — well below the claimed range — which counsel may argue points a PHOSITA toward much lower loadings than the 15-40% (and 20-35%, 25-35%) recited. Counsel may frame this as narrow-overlap plus a directional preference in Friedman that cuts against the high loadings claimed. If pursued as criticality, the argument would benefit from evidence.

• —Friedman claim 2 (retrieved): '...in a concentration of from about 0.01% w/w to about 10% w/w or, from about 0.2% w/w to about 5% w/w'
• —Office action: 'in an amount of about 0.01 to about 20%... that overlaps the range of about 15% to about 40% of instant claim 1'

⚠ Risk The examiner will invoke the prima facie obviousness of overlapping ranges and will likely require objective evidence of criticality of the 15-40% window. PHE caution: arguing that high CBD loading is critical or produces unexpected results may narrow claim scope and create estoppel; a mere directional-preference argument is weaker than a criticality showing.

the lipophilic material comprises propylene glycol monocaprylate

The office action itself states that 'Friedman does not expressly teach propylene glycol monocaprylate,' and the retrieved Friedman claims do not name it; no other asserted reference (Nowak, Stroppolo, Sipernat) is relied on to supply it. The examiner bridges the admitted gap solely with an obvious-variation rationale from propylene glycol dicaprylate/dicaprate (Miglyol 840) cited to Friedman ¶[0010]/[0018]/[0065] — paragraphs that are not present in the retrieved Friedman text and should be verified. Counsel may press that the substitution rationale is conclusory: a mono-ester and a di-/di-ester differ in ester content and emulsification behavior, so the examiner has not articulated why the specific mono-caprylate would predictably substitute. Claim 25 inherits the same admitted gap in addition to its combined narrow carrier/CBD limitations.

• —Office action: 'Although Friedman does not expressly teach propylene glycol monocaprylate of instant claims 1 and 24, Friedman teaches equivalent emulsifiers such as propylene glycol dicaprylate/dicaprate (Miglyol® 840)... and thus, selecting propylene glycol monocaprylate would be obvious variation'
• —Friedman claims (retrieved) do not recite propylene glycol monocaprylate

Risk The examiner will likely respond that propylene glycol mono- and di-caprylate are art-recognized equivalent solubilizers yielding predictable results. Counsel should verify Friedman ¶[0010]/[0018]/[0065] before relying on the record. PHE caution: characterizing propylene glycol monocaprylate as functionally distinct from the di-ester may narrow claim scope in the file wrapper.

an average pore volume of about 2 mL/g to about 2.5 mL/g

The only reference asserted for pore volume is Nowak, and the examiner's own stated Nowak value is 1.2-1.7 mL/g. On the examiner's own numbers, 1.2-1.7 mL/g does not reach the claimed 2-2.5 mL/g sub-range, so the overlapping-range rationale of MPEP § 2144.05 is internally inconsistent as applied to claims 3 and 10. Counsel may argue that no asserted reference discloses a pore volume that overlaps 2-2.5 mL/g. Counsel should confirm Nowak's actual disclosed pore-volume range before relying on this gap, because the 1.2-1.7 figure is itself drawn from an unretrieved Nowak table.

• —Office action: 'a pore volume of 1.2-1.7 mL/g which is within the range of about 0.5mL/g to about 2.5mL/g of instant claim 1 or overlaps the range of about 0.5 to about 1.9mL/g of instant claim 2 or about 2mL/g to about 2.5m/g of instant claim 3'

⚠ Risk The examiner may cite additional Nowak disclosure (or another silica reference) reaching 2-2.5 mL/g. Verify Nowak Table 2/¶[0086] for the true disclosed range before pressing. Minimal estoppel concern.

an average pore diameter of about 2 nm to about 50 nm (claim 7); about 15 nm to about 30 nm (claim 8)

The office action supplies the pore-diameter limitation by converting Nowak's disclosed 'ratio of pore volume to particle size... about 0.001 to about 0.8' into a length expressed in nanometers, reading it as '0.001 microns (=1 nanometer)... to 0.8 microns (=800 nanometer).' The retrieved (fully grounded) Nowak text recites that quantity as a dimensionless ratio, not a pore diameter, so treating it as a nm dimension appears to be a material misreading of what the reference actually says (analysis). For claims 7 and 8, pore diameter is a required element, so if no grounded Nowak text supplies a pore-diameter value, the §103 mapping for those claims is contestable. For independent claim 1 the diameter is only one of three alternatives ('at least one of'), so counsel should weigh this argument against Nowak's surface-area/pore-volume prongs, which the examiner draws from unretrieved paragraphs.

• —Nowak (description excerpt): 'The ratio of pore volume to particle size may range from about 0.001 to about 0.8.'
• —Office action: 'the particles my comprise a diameter of about 0.001 microns (=1 nanometer) microns to 0.8 microns (=800nanometer)... which overlaps the instant ranges of about 2 nm to about 40nm of instant claim 7'

⚠ Risk The examiner may point to unretrieved Nowak paragraphs containing an actual pore-diameter value (verify Table 2/¶[0086] and surrounding text). Separately, for claim 1 the examiner (or examiner on reconsideration) may argue that 'mesoporous' silica inherently denotes 2-50 nm pores under the IUPAC convention, which would independently reach claim 1's diameter prong. No significant estoppel concern from this construction argument.

a porosity of about 60% to about 99% (claims 12-13 sub-ranges)

The porosity limitation is supplied only by Stroppolo's asserted '60-95%' figure attributed to ¶[0018]-[0020], but the retrieved (fully grounded) Stroppolo text — abstract and claims — contains no numerical porosity value. Separately, Stroppolo is directed to a resin-based oral suspension containing an insoluble resin and silica gel at only 0.1%-1.0% w/w, discloses no cannabinoid, and never mentions cannabinoid formulation, which raises a reasonably-pertinent/same-field question under the analogous-art inquiry. Counsel may press both that the porosity figure is not in the grounded text (verify ¶[0018]-[0020]) and that Stroppolo may not be analogous art to the claimed cannabidiol/silica particle. If the porosity limitation is not properly supported, the §103 basis for claims 11-13 is contestable.

• —Stroppolo claim 1 (retrieved): 'A granular composition for oral administration comprising a non soluble resin and a silica gel selected from... Syloid® FP and Syloid® XDP'; claim 4 'Syloid® FP in the range of 0.1%-5% (w/w)'; claim 5 'Syloid® XDP in the range of 0.4%-1.0% (w/w)'
• —Office action: 'as evidenced by Stroppolo... such silicate materials have high porosity of 60-95% (e.g., [0018]-[0020] of Stroppolo)'

Risk The examiner will likely respond that porosity is an inherent material property of the same commercial silica grades (Syloid XDP) regardless of Stroppolo's field or use amount, and that Stroppolo is cited only as evidence. Verify the ¶[0018]-[0020] porosity figures before relying on the mischaracterization. Analogous-art arguments carry moderate risk because the shared silica material may satisfy the 'reasonably pertinent' prong.

a porous solid carrier... comprises a mesoporous silica or an amorphous silica (carrier properties supplied by Nowak)

Every independent claim of Nowak (fully grounded) requires 'two or more active agents' comprising 'at least one cannabinoid and at least one non-cannabinoid therapeutic agent,' and the description is framed around combination products. The instant claims are directed to a drug-containing particle whose drug substance comprises cannabidiol as the cannabinoid, without any required non-cannabinoid therapeutic agent. Counsel may argue that Nowak's teachings are directed to a materially different combination-product platform, which bears on whether a PHOSITA would have looked to Nowak to define the carrier of a single-cannabinoid particle and undercuts the articulated motivation to combine. This does not defeat the carrier-property mapping standing alone, but it weakens the combination rationale the examiner offered.

• —Nowak claim 1 (retrieved): 'a composition... wherein the two or more active agents comprise at least one cannabinoid and at least one non-cannabinoid therapeutic agent'
• —Nowak claim 10 (retrieved): same 'two or more active agents' requirement with a 'porous bead core'

Risk The examiner will likely respond that Nowak is relied on only for the physical properties of its mesoporous silica carrier, not its full composition, and that a carrier's properties are independent of the number of actives it carries. This is a motivation/weighting argument rather than a dispositive missing element.

a drug-containing particle comprising... a lipophilic material at an amount ranging from about 20% to about 35%

Friedman's grounded claims require a self-emulsifying composition built from four cooperating components — a cannabinoid, at least one essential oil or terpene, at least two emulsifiers, and at least one adsorbing powder — in which the cannabinoid is solubilized in the terpene/essential-oil/emulsifier mixture that then self-emulsifies into a sub-micron oil-in-water emulsion on contact with fluids. Counsel may argue the examiner selectively maps individual Friedman ingredients onto the claimed lipophilic material and carrier while not accounting for Friedman's integrated self-emulsifying function, and that the lipophilic-amount overlap (Friedman 1-25% vs. claimed 20-35%; Friedman claim 4 preferring 2-10%) is likewise a narrow sliver skewed toward lower amounts. This is a supporting reading-in-entirety point rather than a dispositive gap given the open 'comprising' format.

• —Friedman claim 1 (retrieved): requires 'at least two emulsifiers' and 'at least one essential oil or at least one terpene' and self-emulsification 'to produce an oil-in-water sub-micron emulsion'
• —Friedman claim 4 (retrieved): hydrophilic emulsifier 'from about 1% w/w to about 20% w/w, preferably from about 2% w/w to about 10% w/w'

Risk Because the instant claims use open 'comprising' language, the presence of additional Friedman components (terpene, second emulsifier) does not by itself defeat the mapping; the examiner may respond that the claimed particle reads on Friedman's adsorbed solid regardless of self-emulsification.

at least one of: average pore volume of about 0.5-2.5 mL/g; average surface area of about 250-600 m²/g; or average pore diameter of about 2-50 nm

The '505 patent claims (fully grounded) require an antioxidant as a mandatory component (element d) and a narrower pore-volume window of about 1-2 mL/g, whereas instant independent claim 1 does not require an antioxidant and recites the three carrier properties in the alternative over broader ranges. Counsel should weigh whether any substantive patentable-distinction argument exists (e.g., the broader/alternative carrier properties and absence of a required antioxidant), while recognizing that a nonstatutory double-patenting rejection of this kind is frequently addressed procedurally rather than on the merits. This entry flags the rejection and its stated basis for counsel's disposition strategy, not a conclusion on patentability.

• —'505 patent claim 1 (retrieved): requires '(d) one or more antioxidants' and 'the porous solid carrier having an average pore volume of about 1 mL/g to 2 mL/g'
• —Office action: 'instant claims require at least one of pore volume, surface area, or pore diameter... in an alternative manner and patent '505 recites inside range of pore volume'

Risk Substantive patentable-distinction arguments over a commonly-owned family member are generally difficult where the instant claims are broader than the patented claims; the examiner will likely maintain the rejection absent a terminal disclaimer. Counsel should evaluate terminal-disclaimer implications on patent term.

cannabidiol... about 15% to about 40% by weight (the 'high amount of CBD' the examiner identifies as the difference)

The claim text of copending Application 18/597,717 was not retrieved and did not resolve to a document on the available record, so the examiner's characterization is the only account of it. Because the reference is unverifiable, counsel should first obtain and confirm the actual pending claims of 18/597,717 before evaluating the examiner's asserted difference (that the instant claims require a higher CBD amount) and the assertion that increasing CBD would be obvious absent criticality evidence. No missing-element or patentable-distinction conclusion should be drawn against 18/597,717 until its claim text is in hand; this rejection is provisional and can be revisited once the copending claims are verified.

• —Office action: 'the instant claims require high amount of CBD, and but it would be obvious to increase the amount of CBD in order to enhance the therapeutic effects... unless there is criticality evidence'
• —Reference grounding: Application 18/597,717 is UNVERIFIABLE — 'this number did not resolve to a document — verify it'

Risk As a provisional rejection over a commonly-owned copending application, disposition will likely turn on the two applications' relative claim scope and a possible terminal disclaimer. Until the 18/597,717 claims are verified, any distinction argued here is unsupported and ranks below every fully-grounded argument.